Novo Nordisk, the Danish drugmaker behind the popular obesity drug Wegovy, warns of fierce competition and market pressures, potentially leading to layoffs. As compounders produce cheaper copycats, U.

The shrinking ranks of "Dividend Knight" contenders. Healthcare stocks with hard times but high yields. What investors should ...

Novo Nordisk is facing a sharp decline in sales of its injectable diabetes drugs, including Ozempic, due to increased competition and potential US tariffs.

Novo Nordisk saw sales growth for its diabetes and obesity care segment slow in the first half of 2025, confirming investor ...

The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped ...

Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Novo Nordisk plans cost cuts amid slower Wegovy growth outlook. Disney’s ESPN to acquire NFL media assets. OpenAI reportedly ...

President Trump’s latest tariff threat has targeted a sector that’s already hobbled.